Healthcare Times Guadeloupe
SEE OTHER BRANDS

Get your health and wellness news from Guadeloupe

Healthcare Times Guadeloupe: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Guadeloupe.

Press releases published on September 4, 2025

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026 Following Q4 2025 and Q1 2026 Regulatory Submissions CRO …

Vireo Growth Inc. Comments on Recent Market Activity; Company Unaware of Any Material Change

Vireo Growth Inc. Comments on Recent Market Activity; Company Unaware of Any Material Change

MINNEAPOLIS , Sept. 04, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. ("Vireo" or the "Company") (CSE: VREO; OTCQX: VREOF), at the request of the Canadian Investment Regulatory Organization (“CIRO”), today confirmed that Company management is unaware of any …

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Morgan Stanley …

Hydreight Announces Closing of its Oversubscribed $11.5 Million Convertible Debenture Offering, Including Full Exercise of Over-Allotment Option

Hydreight Announces Closing of its Oversubscribed $11.5 Million Convertible Debenture Offering, Including Full Exercise of Over-Allotment Option

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or the “Company”), a leader in nationwide digital healthcare solutions, is pleased to announce that it has closed …

Philips launches smart telemetry platform for cardiac monitoring that provides continuous, enterprise-wide connectivity beyond the bedside

Philips launches smart telemetry platform for cardiac monitoring that provides continuous, enterprise-wide connectivity beyond the bedside

September 4, 2025 Empowering clinical teams to respond to surges, track usage and ease workflows with user-friendly touchscreen technology for telemetry patients on the move Cambridge, Massachusetts – Philips, a global leader in health technology, today …

LogicMark Becomes First to Integrate Medication Reminders into Medical Alert Technology

LogicMark Becomes First to Integrate Medication Reminders into Medical Alert Technology

LOUISVILLE, Ky., Sept. 04, 2025 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK) (the “Company”), a provider of personal emergency response systems (PERS), health communication devices, and technology for the growing care economy, today announced the launch …

Dyadic to Present at Investor Conferences and BPI East

Dyadic to Present at Investor Conferences and BPI East

JUPITER, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc., d/b/a Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, …

Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients

Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer Patients

PITTSBURGH, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug development and discovery, and Every Cure, a leading nonprofit dedicated to identifying and validating new uses for existing drugs, today …

Mark Mikhael, CEO of Olympia and Wesley Pharmaceuticals, Named Pharmacist of the Year by the Florida Society of Health-System Pharmacists

Mark Mikhael, CEO of Olympia and Wesley Pharmaceuticals, Named Pharmacist of the Year by the Florida Society of Health-System Pharmacists

ORLANDO, Fla., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Recognized for his leadership in advancing compounding, championing patient access, and shaping the future of pharmacy, Mark Mikhael, PharmD, CEO of Olympia and Wesley Pharmaceuticals, has been named …

Cinq étudiants touchés par la SLA reçoivent la bourse Kevin Daly 2025 de la Société canadienne de la SLA

Cinq étudiants touchés par la SLA reçoivent la bourse Kevin Daly 2025 de la Société canadienne de la SLA

TORONTO, 04 sept. 2025 (GLOBE NEWSWIRE) -- La Société canadienne de la SLA et le fonds Kevin Daly Bursary Fund sont fiers d’annoncer les récipiendaires de la bourse Kevin Daly 2025 de la Société canadienne de la SLA. Cette année, cinq étudiants de niveau …

VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome (ICOMES)

VIVUS Showcases Leadership in Obesity Management at the 2025 International Congress on Obesity and MEtabolic Syndrome (ICOMES)

— Presentations spotlight VIVUS’s 13-year track record of leadership with QSYMIA® (phentermine and topiramate extended-release capsules CIV) in the treatment of obesity and overweight CAMPBELL, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) --  VIVUS LLC, a …

Five students impacted by ALS receive the 2025 ALS Canada Kevin Daly Bursary

Five students impacted by ALS receive the 2025 ALS Canada Kevin Daly Bursary

TORONTO, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The ALS Society of Canada (ALS Canada) and the Kevin Daly Bursary Fund are proud to announce the recipients of the 2025 ALS Canada Kevin Daly Bursary. This year, five post-secondary students with a personal …

“He’s No Prince” PSA Shatters Fairy Tale Illusions to Expose Emotional Abuse

“He’s No Prince” PSA Shatters Fairy Tale Illusions to Expose Emotional Abuse

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- What if Prince Charming wasn’t so charming behind closed doors? The fourth and final installment of The Last I’m Sorry domestic violence awareness campaign, entitled “He’s No Prince” from Safe in Harm’s Way …

Raleigh Orthopaedic Implements Full Athelas Product Suite to Enhance Workflow Efficiency and Patient Care

Raleigh Orthopaedic Implements Full Athelas Product Suite to Enhance Workflow Efficiency and Patient Care

MOUNTAIN VIEW, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Athelas, a healthcare technology company powered by Commure, today announced the implementation of its full product suite with Raleigh Orthopaedic, a leading patient-centered orthopaedic practice in …

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business…

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce Approval from Denali’s Shareholders of the Previously Announced Business…

PALO ALTO, Calif, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Semnur Pharmaceuticals, Inc. (“Semnur”), a majority-owned subsidiary of Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, …

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025

SUNNYVALE, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- - BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that BioCardia’s President and CEO, …

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment

Dr. Robert Schwartz, Chief Medical Officer of Autonomix, discusses the Company’s recently announced results from the post hoc analysis of its proof-of-concept human clinical trial (“PoC 1”) THE WOODLANDS, TX, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Autonomix …

Bonafide® Health Announces Expansion to Retail with Exclusive Launch into 1,800+ Target Stores and Target.com

Bonafide® Health Announces Expansion to Retail with Exclusive Launch into 1,800+ Target Stores and Target.com

New York, NY, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Bonafide Health, LLC, a leading direct-to-consumer women’s healthcare company that provides clinically researched solutions to effectively relieve perimenopause …

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

Artelo Biosciences Announces Pricing of $3.0 Million Public Offering

SOLANA BEACH, Calif., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic …

Branded Legacy, Inc. Expands Capabilities with Acquisition of State-of-the-Art GMP Facility in Vancouver

Branded Legacy, Inc. Expands Capabilities with Acquisition of State-of-the-Art GMP Facility in Vancouver

VANCOUVER, British Columbia, Sept. 04, 2025 (GLOBE NEWSWIRE) -- via IBN -- Branded Legacy, Inc. (OTC: BLEG), a pioneering biotechnology company dedicated to revolutionizing addiction treatment and harm reduction solutions, today announced that its …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions